Interfering with diabetes

Type 1 Diabetes Insulin, discovered a century ago, remains the mainstay of treatment for type 1 diabetes, as autoimmunity destroys the patients' insulin-producing pancreatic β cells. A study by Quattrin et al. indicates that it may be possible to slow down the progression of this disease. In this phase 2 clinical trial, young patients with newly diagnosed type 1 diabetes were treated with golimumab, an antibody against the cytokine tumor necrosis factor–α, and compared with a placebo group. Although golimumab did not fully prevent disease progression, it produced partial remissions and decreased the amount of insulin required, offering a potentially promising addition to the therapeutic options for this patient group. N. Engl. J. Med. 383 , 2007 (2020).